Adma Biologics (ADMA) Finished Goods (2017 - 2025)

Adma Biologics' Finished Goods history runs 9 years deep, the most recent figure standing at $52.1 million for Q4 2025.

• Quarterly Finished Goods rose 8.18% year-over-year to $52.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.1 million (up 8.18% YoY) and the FY2025 annual result came in at $52.1 million, up 8.18% from the prior year.
• Finished Goods was $52.1 million for Q4 2025 at Adma Biologics, down from $64.3 million in the prior quarter.
• Across five years, Finished Goods topped out at $70.3 million in Q4 2023 and bottomed at $17.5 million in Q2 2021.
• A 5-year average of $51.5 million and a median of $52.3 million in 2023 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2022 — Finished Goods soared 257.16% — and 2025, when it slumped 32.47%.
• Adma Biologics' Finished Goods stood at $29.0 million in 2021, then surged by 101.6% to $58.5 million in 2022, then advanced by 20.22% to $70.3 million in 2023, then tumbled by 31.54% to $48.1 million in 2024, then climbed by 8.18% to $52.1 million in 2025.
• Business Quant data shows ADMA's Finished Goods at $52.1 million in Q4 2025, $64.3 million in Q3 2025, and $47.9 million in Q2 2025.